• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scienture Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    11/14/25 5:00:35 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care
    Get the next $SCNX alert in real time by email
    false 0001382574 0001382574 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 12, 2025

     

    SCIENTURE HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-39199   46-3673928

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File No.)

     

    (I.R.S. Employer

    Identification No.)

     

    20 Austin Blvd.
    Commack, NY 11725
    (Address of Principal Executive Offices)

     

    (631) 670-6039
    (Registrant’s Telephone Number)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.00001 per share   SCNX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    Scienture Holdings, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders both (the “Annual Meeting”) virtually via a live webcast on November 12, 2025. The Company’s stockholders voted on six proposals at the Annual Meeting, each of which is listed below and described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on October 24, 2025. With respect to each proposal, holders of the Company’s common stock, par value $0.00001 (the “Common Stock”) were entitled to cast one vote per share of Common Stock held as of the close of business on the record date of September 25, 2025. At the beginning of the Annual Meeting, holders of Common Stock representing 10,990,183 votes were represented in person or by proxy at the Annual Meeting, which represented 52.01% of the voting power of the 21,132,260 shares of Common Stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business.

     

    At the Annual Meeting, the Company’s stockholders voted on the following proposals:

     

      1. To elect five directors to the Company’s board of directors (the “Board”), each to serve a term of one year and until their respective successors have been elected and qualified, or until their earlier resignation or removal;

     

      2. To consider and approve an Amendment to the Second Amended and Restated Certificate of Incorporation (the “Charter”) to increase the number of shares of Common Stock, authorized for issuance from 100,000,000 shares to 2,000,000,000 shares and of preferred stock, $0.00001 par value per share (the “Preferred Stock”), authorized for issuance from 10,000,000 shares to 200,000,000 shares;

     

      3. To consider and approve an Amendment to the Second Amended and Restated 2019 Equity Incentive Plan (the “2019 Plan”) to increase the number of shares of Common Stock available for issuance under the 2019 Plan from 5,000,000 shares to 25,000,000 shares;

     

      4. To consider and approve a potential future offering of Common Stock, which could result in the issuance of more than 20% of the currently outstanding shares of Common Stock at a price below the “minimum price,” as defined by, and in accordance with, Nasdaq Listing Rule 5635(d);
         
     

    5.

     

    To consider and vote on a proposal to grant the Board the discretion to amend the Charter to effect a reverse stock split at a ratio of not less than one-for-two and not greater than one-for-fifty, with the exact ratio to be set within that range at the discretion of the Board without further approval or authorization of the stockholders; and
         
      6. To approve an adjournment of the Annual Meeting, if necessary and appropriate, as determined by the Board in its sole discretion, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve the presented proposals or to constitute a quorum.

     

    The final results of voting on each of the proposals presented at the Annual Meeting, as certified by the Company’s independent inspector of election, are set forth below.

     

     

     

     

    Proposal No. 1: Election of Directors.

     

    The stockholders elected each of the five director nominees to serve on the Board until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal. The results of the vote taken were as follows:

    Nominee  Votes For   Votes Against   Abstentions   Broker Non-
    Votes
     
    Mayur Doshi   9,875,664    952,915         -    161,604 
    Donald G. Fell   9,491,711    1,336,868    -    161,604 
    Shankar Hariharan   10,714,392    114,187    -    161,604 
    Subbarao Jayanthi   9,517,166    1,311,413    -    161,604 
    Narasimhan Mani   9,959,634    868,945    -    161,604 

     

    Proposal No. 2: Approval of the Amendment to the Charter to increase the number of shares of Common Stock, authorized for issuance from 100,000,000 shares to 2,000,000,000 shares and of Preferred Stock, authorized for issuance from 10,000,000 shares to 200,000,000 shares.

     

    The stockholders of the Company rejected the amendment to the Charter to increase the number of shares of Common Stock, authorized for issuance from 100,000,000 shares to 2,000,000,000 shares and of Preferred Stock, authorized for issuance from 10,000,000 shares to 200,000,000 shares. The results of the vote taken were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    5,326,576   5,501,986   17   161,604

     

    Proposal No. 3: Approval of the Amendment to the 2019 Plan to increase the number of shares of Common Stock available for issuance thereunder from 5,000,000 shares to 25,000,000 shares.

     

    The stockholders of the Company approved the amendment to the 2019 Plan to increase the number of shares of Common Stock available for issuance from 5,000,000 shares to 25,000,000 shares. The results of the vote taken were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    5,599,253   5,229,326   -   161,604

     

    Proposal No. 4: Approval of a potential future offering of Common Stock, which could result in the issuance of more than 20% of the currently outstanding shares of Common Stock at a price below the “minimum price,” as defined by, and in accordance with, Nasdaq Listing Rule 5635(d).

     

    The stockholders of the Company approved the proposal of a potential future offering of Common Stock, which could result in the issuance of more than 20% of the currently outstanding shares of Common Stock at a price below the “minimum price,” as defined by, and in accordance with, Nasdaq Listing Rule 5635(d). The results of the vote taken were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    5,607,934   5,220,045   600   161,604

     

    Proposal No. 5: Approval to grant the Board the discretion to amend the Charter to effect a reverse stock split at a ratio of not less than one-for-two and not greater than one-for-fifty, with the exact ratio to be set within that range at the discretion of the Board without further approval or authorization of the stockholders.

     

    The stockholders of the Company approved the proposal to grant the Board the discretion to amend the Charter to effect a reverse stock split at a ratio of not less than one-for-two and not greater than one-for-fifty, with the exact ratio to be set within that range at the discretion of the Board without further approval or authorization of the stockholders. The results of the vote taken were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    6,276,243   4,713,433   507   -

     

    Proposal No. 6: Approval of an adjournment of the Annual Meeting, if necessary and appropriate, as determined by the Board in its sole discretion, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve the presented proposals or to constitute a quorum.

     

    The stockholders of the Company approved the proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies if there were insufficient votes to approve the presented proposals or to constitute a quorum. Although this proposal was approved by the Company’s stockholders, because there was a quorum present and there were sufficient votes represented at the time of the Annual Meeting to approve the proposals, adjournment of the Annual Meeting was deemed unnecessary. The results of the vote taken were as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    9,616,062   1,343,481   30,640   —

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      SCIENTURE HOLDINGS, INC.
         
      By: /s/ Dr. Narasimhan Mani
        Dr. Narasimhan Mani
        Co-Chief Executive Officer
         
    Date: November 14, 2025    

     

     

    Get the next $SCNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCNX
    Leadership Updates

    Live Leadership Updates

    View All

    SCIENTURE Announces Executive Leadership Transition

    TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

    5/22/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    SEC Filings

    View All

    Scienture Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    11/14/25 5:00:35 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    11/13/25 5:00:35 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Scienture Holdings Inc.

    10-Q - Scienture Holdings, Inc. (0001382574) (Filer)

    11/12/25 5:30:11 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update

    Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli™, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertension COMMACK, NY, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the third quarter ended September 30, 2025. Third Quarter 202

    11/13/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans

    Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans. This inclusion extends availability to over

    11/4/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

    Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced the start of commercial sales and fulfillment of the first customer order

    10/23/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care